Hep C drug also active against zika

May 19, 2016 News BioVox

Scientists from KU Leuven have shown that the experimental antiviral drug 7DMA against hepatitis C slows down the development of the Zika virus in mice. The study, carried out by the Laboratory of Virology and Chemotherapy and led by Prof. Johan Neyts also disposes of a panel of experimental assays to identify inhibitors of the zika virus and an animal model to study zika- infection.
So far no vaccine or antiviral therapies are available for the prevention or treatment of zika infections, which can result in neurological and auto-immune complications in infants and adults.


Reference

Zmurko et al. The Viral Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLOS neglected tropical diseases (2016)

 


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts